Re-Evaluating Clonal Dominance in Cancer Evolution

Trends in Cancer

Volumn 2, Issue 5, 2016, Pages 263-276

  Burrell, Rebecca A ^a   Swanton, Charles ^a,b  

^a THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER THERAPY; CLONAL EVOLUTION; GENETIC HETEROGENEITY; GENETIC VARIATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ANIMAL; GENETICS; NEOPLASM; PATHOLOGY;

ANIMALS; CLONAL EVOLUTION; GENETIC HETEROGENEITY; HUMANS; NEOPLASMS;

EID: 84968754681     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2016.04.002     Document Type: Review

References (103)

1. P.C. Nowell The clonal evolution of tumor cell populations Science 194 1976 23 28
2. M. Greaves, and C.C. Maley Clonal evolution in cancer Nature 481 2012 306 313
3. M. Gerlinger, and et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing Nat. Genet. 46 2014 225 233
4. D.A. Landau, and et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia Cell 152 2013 714 726
5. R.A. Burrell, and C. Swanton Tumour heterogeneity and the evolution of polyclonal drug resistance Mol. Oncol. 8 2014 1095 1111
6. N. McGranahan, and C. Swanton Biological and therapeutic impact of intratumor heterogeneity in cancer evolution Cancer Cell 27 2015 15 26
7. C.G. Mullighan, and et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia Science 322 2008 1377 1380
8. J.J. Keats, and et al. Clonal competition with alternating dominance in multiple myeloma Blood 120 2012 1067 1076
9. L. Ding, and et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing Nature 481 2012 506 510
10. J.S. Welch, and et al. The origin and evolution of mutations in acute myeloid leukemia Cell 150 2012 264 278
11. A. Sottoriva, and et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics Proc. Natl. Acad. Sci. U. S. A. 110 2013 4009 4014
12. A.S. Morrissy, and et al. Divergent clonal selection dominates medulloblastoma at recurrence Nature 529 2016 351 357
13. M. Castellarin, and et al. Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease J. Pathol. 229 2013 515 524
14. A. Bashashati, and et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling J. Pathol. 231 2013 21 34
15. R.F. Schwarz, and et al. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis PLoS Med. 12 2015 e1001789
16. L.R. Yates, and et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing Nat. Med. 21 2015 751 759
17. S. Nik-Zainal, and et al. The life history of 21 breast cancers Cell 149 2012 994 1007
18. S.P. Shah, and et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers Nature 486 2012 395 399
19. M. Gerlinger, and et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N. Engl. J Med. 366 2012 883 892
20. E.C. de Bruin, and et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution Science 346 2014 251 256
21. N. Murugaesu, and et al. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy Cancer Discov. 5 2015 821 831
22. C.S. Cooper, and et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue Nat. Genet. 47 2015 367 372
23. P.C. Boutros, and et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer Nat. Genet. 47 2015 736 745
24. D. Brocks, and et al. Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer Cell Rep. 8 2014 798 806
25. S. Yachida, and et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer Nature 467 2010 1114 1117
26. S. Ling, and et al. Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution Proc. Natl. Acad. Sci. U. S. A. 112 2015 E6496 E6505
27. N.J. Szerlip, and et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response Proc. Natl. Acad. Sci. U. S. A. 109 2012 3041 3046
28. M. Snuderl, and et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma Cancer Cell 20 2011 810 817
29. S. Nik-Zainal, and et al. Mutational processes molding the genomes of 21 breast cancers Cell 149 2012 979 993
30. A. Kumar, and et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer Nat. Med. 22 2016 369 378
31. H. Shi, and et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy Cancer Discov. 4 2014 80 93
32. D. Juric, and et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kalpha inhibitor Nature 518 2015 240 244
33. M. Janiszewska, and et al. In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer Nat. Genet. 47 2015 1212 1219
34. A. Sottoriva, and et al. A Big Bang model of human colorectal tumor growth Nat. Genet. 47 2015 209 216
35. B. Waclaw, and et al. A spatial model predicts that dispersal and cell turnover limit intratumour heterogeneity Nature 525 2015 261 264
36. B.E. Johnson, and et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma Science 343 2014 189 193
37. N. Bolli, and et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma Nat. Commun. 5 2014 2997
38. T. Kim, and et al. Clonal dynamics in a single AML case tracked for 9 years reveals the complexity of leukemia progression Leukemia 30 2015 295 302
39. M.S. Lawrence, and et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes Nature 499 2013 214 218
40. K. Anderson, and et al. Genetic variegation of clonal architecture and propagating cells in leukaemia Nature 469 2011 356 361
41. D.A. Landau, and et al. Mutations driving CLL and their evolution in progression and relapse Nature 526 2015 525 530
42. J.G. Lohr, and et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy Cancer Cell 25 2014 91 101
43. E.M. Van Allen, and et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma Cancer Discov. 4 2014 94 109
44. I. Bozic, and M.A. Nowak Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers Proc. Natl. Acad. Sci. U. S. A. 111 2014 15964 15968
45. S.V. Sharma, and et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations Cell 141 2010 69 80
46. M. Greaves Evolutionary determinants of cancer Cancer Discov. 5 2015 806 820
47. C. Bettegowda, and et al. Detection of circulating tumor DNA in early- and late-stage human malignancies Sci. Transl. Med. 6 2014 224ra24
48. G. Siravegna, and et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients Nat. Med. 21 2015 827
49. S. Misale, and et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer Nature 486 2012 532 536
50. S. Misale, and et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer Sci. Transl. Med. 6 2014 224ra26
51. A. Bardelli, and et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer Cancer Discov. 3 2013 658 673
52. M. Murtaza, and et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer Nat. Commun. 6 2015 8760
53. N. McGranahan, and et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution Sci. Transl. Med. 7 2015 283ra54
54. P.J. Stephens, and et al. The landscape of cancer genes and mutational processes in breast cancer Nature 486 2012 400 404
55. M. Gerlinger, and et al. Cancer: evolution within a lifetime Annu. Rev. Genet. 48 2014 215 236
56. E.D. Pleasance, and et al. A small-cell lung cancer genome with complex signatures of tobacco exposure Nature 463 2010 184 190
57. S.A. Roberts, and et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers Nat. Genet. 45 2013 970 976
58. B.J. Taylor, and et al. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis Elife 2 2013 e00534
59. C. Swanton, and et al. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity Cancer Discov. 5 2015 704 712
60. R. Govindan, and et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers Cell 150 2012 1121 1134
61. M. Imielinski, and et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing Cell 150 2012 1107 1120
62. P.C. Galipeau, and et al. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus Proc. Natl. Acad. Sci. U. S. A. 93 1996 7081 7084
63. S.L. Carter, and et al. Absolute quantification of somatic DNA alterations in human cancer Nat. Biotechnol. 30 2012 413 421
64. S.M. Dewhurst, and et al. Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution Cancer Discov. 4 2014 175 185
65. P. Eirew, and et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution Nature 518 2015 422 426
66. L.A. Diaz, and et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers Nature 486 2012 537 540
67. M.J. Williams, and et al. Identification of neutral tumor evolution across cancer types Nat. Genet. 48 2016 238 244
68. C. Tomasetti, and et al. Only three driver gene mutations are required for the development of lung and colorectal cancers Proc. Natl. Acad. Sci. U. S. A. 112 2015 118 123
69. D.P. Tabassum, and K. Polyak Tumorigenesis: it takes a village Nat. Rev. Cancer 15 2015 473 483
70. A.S. Cleary, and et al. Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers Nature 508 2014 113 117
71. A. Marusyk, and et al. Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity Nature 514 2014 54 58
72. M.M. Inda, and et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma Genes Dev. 24 2010 1731 1745
73. A. Chapman, and et al. Heterogeneous tumor subpopulations cooperate to drive invasion Cell Rep. 8 2014 688 695
74. F. Mateo, and et al. SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations Mol. Cancer 13 2014 237
75. J. Calbo, and et al. A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer Cancer Cell 19 2011 244 256
76. M.C. Kwon, and et al. Paracrine signaling between tumor subclones of mouse SCLC: a critical role of ETS transcription factor Pea3 in facilitating metastasis Genes Dev. 29 2015 1587 1592
77. S. Hobor, and et al. TGFalpha and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells Clin. Cancer Res. 20 2014 6429 6438
78. N. Aceto, and et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis Cell 158 2014 1110 1122
79. T.A. Yap, and et al. Intratumor heterogeneity: seeing the wood for the trees Sci. Transl. Med. 4 2012 127ps10
80. M. Inukai, and et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer Cancer Res. 66 2006 7854 7858
81. S. Maheswaran, and et al. Detection of mutations in EGFR in circulating lung-cancer cells N. Engl. J. Med. 359 2008 366 377
82. A.B. Turke, and et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC Cancer Cell 17 2010 77 88
83. A.N. Hata, and et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition Nat. Med. 22 2016 262 269
84. J. Richman, and et al. BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma Expert Opin. Pharmacother. 16 2015 1285 1297
85. I. Bozic, and et al. Evolutionary dynamics of cancer in response to targeted combination therapy Elife 2 2013 e00747
86. L.V. Sequist, and et al. Rociletinib in EGFR-mutated non-small-cell lung cancer N. Engl. J. Med. 372 2015 1700 1709
87. Z. Piotrowska, and et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor Cancer Discov. 5 2015 713 722
88. M.E. Hammond, and et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J. Clin. Oncol. 28 2010 2784 2795
89. G. Early Breast Cancer Trialists' Collaborative, and et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials Lancet 378 2011 771 784
90. R.A. Burrell, and et al. Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer J. Cell Biochem. 111 2010 782 790
91. P.K. Brastianos, and et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets Cancer Discov. 5 2015 1164 1177
92. P.I. Poulikakos, and et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 464 2010 427 430
93. M. Das Thakur, and et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance Nature 494 2013 251 255
94. P.M. Enriquez-Navas, and et al. Application of evolutionary principles to cancer therapy Cancer Res. 75 2015 4675 4680
95. J.R. Brahmer, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N. Engl. J. Med. 366 2012 2455 2465
96. J. Brahmer, and et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N. Engl. J. Med. 373 2015 123 135
97. T.N. Schumacher, and R.D. Schreiber Neoantigens in cancer immunotherapy Science 348 2015 69 74
98. N.A. Rizvi, and et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer Science 348 2015 124 128
99. A. Snyder, and et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma N. Engl. J. Med. 371 2014 2189 2199
100. E.M. Van Allen, and et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma Science 350 2015 207 211
101. I. Melero, and et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer Nat. Rev. Cancer 15 2015 457 472
102. N. McGranahan, and et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade Science 351 2016 1463 1469
103. M. Jamal-Hanjani, and et al. Tracking genomic cancer evolution for precision medicine: the lung TRACERx study PLoS Biol. 12 2014 e1001906